Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412515 | 0.80 | HTR2C (0.40) | CA12CA9CA1CA2CA4 | |
| SCHEMBL29681708 | 0.78 | KEAP1 (0.44) | CA12CA9CA1CA2CA4 | |
| SCHEMBL61176 | 0.78 | KEAP1 (0.44) | CA12CA9CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL7399331 | 0.77 | KEAP1 (0.43) | CA12CA9CA1CA2CA4 | |
| SCHEMBL29412491 | 0.72 | KEAP1 (0.40) | CA12CA9CA1CA2CA4 | |
| SCHEMBL22695019 | 0.68 | OPRL1 (0.36) | CA12CA9CA1CA2CA4 | |
| SCHEMBL29412547 | 0.67 | KEAP1 (0.54) | CA12CA9CA1CA2CA4 | |
| SCHEMBL710185 | 0.67 | KEAP1 (0.50) | CA12CA9CA1CA2CA4 | |
| SCHEMBL7487953 | 0.67 | CA12 (0.48) | CA12CA9CA1CA2CA4 | |
| SCHEMBL27595871 | 0.67 | PLCG1 (0.36) | CA12CA9CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) | 2010-07-29 | — | — | US | claimed |
| EP-2064197-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) | 2009-06-03 | — | — | EP | claimed |
| WO-2008020256-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) | 2008-02-21 | — | — | WO | claimed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | claimed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) | 2010-07-29 | — | — | US | disclosed |
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) | 2010-07-29 | — | — | US | disclosed |
| CN-101547912-A | 3, 4-dihydrobenzo [1, 2, 3] thiadiazine-1, 1-dioxide derivatives, method for the production thereof, medicaments containing said derivatives and the use thereof | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-09-30 | — | — | CN | disclosed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| EP-2064197-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) | 2009-06-03 | — | — | EP | disclosed |
| EP-2064197-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) | 2009-06-03 | — | — | EP | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| WO-2005080391-A1 | PRODRUGS OF SUBSTITUTED AMINO HETEROBICYCLES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004074290-A1 | SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | disclosed |
| CN-1293665-A | New compounds and their use as positive AMPA receptor modulators | NEUROSEARCH AS (DK) | 2001-05-02 | — | — | CN | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | CA12 3409/4885CA9 1583/4885CA1 2279/4885 |
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | TDO2, DHODH, DHPS | CA12 3434/4885CA9 4233/4885CA1 2614/4885 |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | CA12 3409/4885CA9 1583/4885CA1 2279/4885 |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | CA12 1624/4885CA9 3703/4885CA1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.